Umbralisib
Kinase Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: TGR-1202, ukoniq, umbralisib tosylate
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Umbralisib is an ofm drug in the Kinase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2021. Its mechanism of action is classified as Kinase Inhibitors. DrugCentral lists 5 molecular targets, including PIK3CD, CSNK1E and PIK3CG. Recorded indications include Relapsed or refractory follicular lymphoma and Relapsed or refractory marginal zone lymphoma.
- Approval status: ofm (first approved 2021 by the FDA).
- Drug class: Kinase Inhibitor.
- Mechanism of action: Kinase Inhibitors.
- Molecular targets: PIK3CD, CSNK1E, PIK3CG and PIK3CA (5 listed in DrugCentral).
- Indications: Relapsed or refractory follicular lymphoma and Relapsed or refractory marginal zone lymphoma.
- ATC code: L01EX25 (Other protein kinase inhibitors).
- Molecular formula: C31H24F3N5O3; molecular weight 571.56 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Relapsed or refractory follicular lymphoma
- Relapsed or refractory marginal zone lymphoma
Mechanism & targets
| Mechanism of action (MoA) | Kinase Inhibitors |
|---|---|
| Established pharmacologic class | Kinase Inhibitor |
Molecular targets (5)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | PIK3CD | inhibitor | Kd 8.21 |
| Casein kinase I isoform epsilon | CSNK1E | inhibitor | Kd 6.74 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | PIK3CG | inhibitor | Kd 5.85 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | PIK3CA | inhibitor | Kd 5.00 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | PIK3CB | inhibitor | Kd 5.00 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2021-02-05 | FDA | — | TG THERAPEUTICS Inc | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L01EX25 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PROTEIN KINASE INHIBITORS › Other protein kinase inhibitors |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Nervous system disorder | 60.2 |
| Immunodeficiency common variable | 49.5 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Umbralisib is on its molecule page.
| Molecular formula | C31H24F3N5O3 |
|---|---|
| Molecular weight | 571.56 g/mol |
| CAS number | 1532533-67-7 |
| InChIKey | IUVCFHHAEHNCFT-INIZCTEOSA-N |
| PubChem CID | 72950888 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Umbralisib used for?
DrugCentral lists the following indications for Umbralisib: Relapsed or refractory follicular lymphoma and Relapsed or refractory marginal zone lymphoma.
How does Umbralisib work?
Umbralisib is classified as Kinase Inhibitors; its molecular targets in DrugCentral include PIK3CD (inhibitor), CSNK1E (inhibitor), PIK3CG (inhibitor) and PIK3CA (inhibitor).
When was Umbralisib first approved?
Umbralisib was first approved by the FDA in 2021.
What drug class does Umbralisib belong to?
Umbralisib is in the Kinase Inhibitor class.
What is the chemical formula of Umbralisib?
Umbralisib has the molecular formula C31H24F3N5O3 and a molecular weight of 571.56 g/mol.
Browse: all drugs starting with U · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5441 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL3948730 — compound record and bioactivity
- PubChem CID 72950888 — chemical identifiers
- DrugBank DB14989 — drug record
- FDA UNII 38073MQB2A — substance identity
- DailyMed: FDA labels for Umbralisib — current prescribing information (label search)
- UniProt O00329 (PIK3CD) — target protein
- UniProt P49674 (CSNK1E) — target protein
- UniProt P48736 (PIK3CG) — target protein
- UniProt P42336 (PIK3CA) — target protein
- UniProt P42338 (PIK3CB) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.